Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 151-160 of 201 for melanoma

Edit search filters
  1. Detection of Mutant Circulating Tumor (CT)Dna in Uveal Melanoma With Development of a Droplet Digital Pcr (Ddpcr) Assay

    Rochester, MN

  2. MElanoma Research Lymph node prediction Implementation National_001 (MERLIN_001)

    Rochester, MN

  3. Circulating Tumor Nucleic Acids to Monitor Treatment Response in Metastatic Melanoma Patients

    Scottsdale/Phoenix, AZ

  4. Innovative CAR-TIL immunotherapy against melanoma

    Jacksonville, FL

  5. Validation of a Blood Assay for the Detection of BRAF Mutation Status in Patients with Metastatic Melanoma

    Rochester, MN

  6. Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

    Rochester, MN

  7. Study of Immunotherapy and Ovarian Function Among Premenopausal Melanoma Survivors

    Rochester, MN

  8. Reporting of Side Effects Among Stage III and IV Melanoma Patients Treated with Immune Checkpoint Inhibitors

    Rochester, MN

  9. A Study of DNA Markers for the Detection of Metastatic Melanoma in Blood

    Rochester, MN

  10. Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients

    Rochester, MN

.

Mayo Clinic Footer